We have a dedicated CRISPR group that has amassed extensive knowledge, enabling us to stay at the cutting edge of this groundbreaking field.
Gene-editing technologies such as zinc fingers, TALENs, and CRISPR, along with their applications in areas such as diagnostics and therapeutics, have been a prominent topic in recent years. Murgitroyd’s CRISPR group has acquired extensive knowledge through their involvement with the manipulation of CRISPR systems for food applications since 2007, evolving alongside the technology itself and expanding into various other applications.
Having been at the forefront of this emerging technology, Murgitroyd is adept at guiding clients through the intricate patent landscape, offering proactive and pragmatic commercial advice. We possess a deep understanding of how patent offices are approaching this technology and the type of data required to establish robust patent protection, depending on the application of the technology within the invention.
We have an in-depth understanding of the diverse applications of various classes and types of CRISPR systems and stay updated with developments in this field. Our experience encompasses not only human therapeutics but also industrial biotechnology, microbiome, AgBio, and AI.
Our expertise is well-regarded within our industry, and we are frequently consulted for commentary by IP journals such as IAM, LSIPR, and MIP, as well as scientific publications such as Nature and Science. At the request of the Chartered Institute of Patent Attorneys, we have delivered presentations to fellow UK patent attorneys on considerations for drafting in this area.
Our collaborative environment enables us to assemble a team tailored to the specific needs of our clients. Our core team includes experts in CRISPR systems, AI, plant sciences, oppositions and pharmaceuticals.